Partner With OneThree
Together we can discover new medicines at an unprecedented scale by generating new insights to accelerate your internal R&D or identifying new therapeutics to fill your pipeline
Testimonials
"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work. I expect that this approach will be integral to the future of drug discovery."
Josh Allen, PhD
Chief Science Officer
"We are very impressed with the quality and speed of work performed by OneThree in applying their AI expertise to identify novel drug candidates for RSV from our unique human challenge trial data. Poolbeg will now progress to validate these drug candidates for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited.”
Jeremy Skillington, PhD
CEO, Poolbeg Pharma
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection. We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
Syed Kazmi
CEO, Jubilant Therapeutics
"We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."
Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier. The speed and applicability of this platform for drug discovery is unprecedented."
Paraskevi Giannakakou, PhD
Director of Lab Research (Heme/Onc), Weill Cornell
"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work."
"I expect that this approach will be integral to the future of drug discovery."
"I expect that this approach will be integral to the future of drug discovery."
Josh Allen, PhD
Chief Science Officer
"We are very impressed with the quality and speed of work performed by OneThree in applying their AI expertise to identify novel drug candidates for RSV from our unique human challenge trial data. Poolbeg will now progress to validate these drug candidates for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited.”
Jeremy Skillington, PhD
CEO, Poolbeg Pharma
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection."
"We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
Syed Kazmi
CEO, Jubilant Therapeutics
" We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."
Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier."
"The speed and applicability of this platform for drug discovery is unprecedented."
"The speed and applicability of this platform for drug discovery is unprecedented."
Paraskevi Giannakakou, PhD
Director of Laboratory Research (Heme/Onc)
"OneThree's platform helped solve problems that we had been working on for years and potentially saved several years of additional work."
"I expect that this approach will be integral to the future of drug discovery."
"I expect that this approach will be integral to the future of drug discovery."
Josh Allen, PhD
Chief Science Officer
"We are very impressed with the quality and speed of work performed by OneThree in applying their AI expertise to identify novel drug candidates for RSV from our unique human challenge trial data. Poolbeg will now progress to validate these drug candidates for further development in RSV, the only one of the three main respiratory illnesses for which there are not yet any approved vaccines and where treatment options are limited.”
Jeremy Skillington, PhD
CEO, Poolbeg Pharma
"The convergence of biology and scalable data science is enabling new approaches to de-risk early-stage programs through biomarker discovery and patient selection."
"We are pleased to collaborate with OneThree Biotech in the application of their proven biology-driven AI approach."
Syed Kazmi
CEO, Jubilant Therapeutics
" We are very excited to partner with OneThree Biotech on this unique project, as insights gleaned through their biology-driven AI platform will give fresh impetus to our drug discovery programs."
Rajesh Raganathan
VP Partnerships and Portfolio Strategy, SPARC
"Discoveries like this would have been nearly impossible earlier."
"The speed and applicability of this platform for drug discovery is unprecedented."
"The speed and applicability of this platform for drug discovery is unprecedented."
Paraskevi Giannakakou, PhD
Director of Laboratory Research (Heme/Onc)
Our Partners and Collaborators
Previous
Next
Explore our publications, news,
case studies and blogs to learn more.
case studies and blogs to learn more.
Please contact us
to discuss your specific needs!
to discuss your specific needs!